Metabolic regulation of the cancer-immunity cycle

免疫监视 免疫系统 免疫检查点 肿瘤微环境 免疫学 癌变 生物 癌症 免疫 免疫疗法 癌症研究 遗传学
作者
Luis F. Somarribas Patterson,Santosha A. Vardhana
出处
期刊:Trends in Immunology [Elsevier BV]
卷期号:42 (11): 975-993 被引量:48
标识
DOI:10.1016/j.it.2021.09.002
摘要

Elevated tumor glycolysis and lactate production are robust suppressors of antitumor immunity in multiple cancer subtypes. Loss of mitochondrial function is a hallmark of CD8+ T cell exhaustion and might be a promising metabolic target for improving patient responses to CAR-T and/or ICB therapy, pending future investigations. IL4I1-driven tryptophan catabolism and aryl hydrocarbon receptor activation may constitute a resistance mechanism to ICB and/or IDO1 inhibitors across cancer subtypes. We propose that the metabolic profile of the TME promotes both initiation and disruption of the cancer-immunity cycle. Hence, targeting cellular metabolism in the TME may improve responsiveness to T cell-based immunotherapies. The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth. Interruption of one or more steps of the CIC enables tumors to evade immunosurveillance. However, attempts to restore antitumor immunity by reactivating the CIC have had limited success thus far. Recently, numerous studies have implicated metabolic reprogramming of tumor and immune cells within the tumor microenvironment (TME) as key contributors to immune evasion. In this opinion, we propose that alterations in cellular metabolism during tumorigenesis promote both initiation and disruption of the CIC. We also provide a rationale for metabolically targeting the TME, which may assist in improving tumor responsiveness to chimeric antigen receptor (CAR)-transduced T cells or immune checkpoint blockade (ICB) therapies. The cancer-immunity cycle (CIC) comprises a series of events that are required for immune-mediated control of tumor growth. Interruption of one or more steps of the CIC enables tumors to evade immunosurveillance. However, attempts to restore antitumor immunity by reactivating the CIC have had limited success thus far. Recently, numerous studies have implicated metabolic reprogramming of tumor and immune cells within the tumor microenvironment (TME) as key contributors to immune evasion. In this opinion, we propose that alterations in cellular metabolism during tumorigenesis promote both initiation and disruption of the CIC. We also provide a rationale for metabolically targeting the TME, which may assist in improving tumor responsiveness to chimeric antigen receptor (CAR)-transduced T cells or immune checkpoint blockade (ICB) therapies. catabolic pathway that oxidizes glucose to pyruvate and subsequently reduces pyruvate to lactate. The latter step often occurs in anaerobic or hypoxic conditions, but under aerobic conditions in rapidly proliferating cells. programmed cell death caused by detachment of a cell from the extracellular matrix. target cyclin-dependent kinase 4 and 6; known for their ability to inhibit progression through the G1 phase of the cell cycle and, consequently, inhibit cell proliferation, including that of cancer cells. phenotype adopted by proliferating cells in response to stress or damage; characterized by an arrest in the cell cycle. T cell genetically engineered to increase antigen-specific T cell recognition of tumors. CARs contain an extracellular antigen-recognition domain and up to three intracellular signaling domains that activate T cells. Certain CAR T cells may be adoptively transferred to patients. molecules released by damage or dying cells that elicit immune responses through binding pattern recognition receptors. hydrolyzes nucleotide anhydride or ester bonds, producing nucleosides. catabolic pathway that promotes the oxidation of one molecule of glucose and produces two molecules of pyruvate. elevated number of somatic mutations in the genome of a cell. component of an inhibitory pathway intrinsic to the immune system that regulates the duration and amplitude of immune responses. antagonism of immune checkpoint function via therapeutic agents, mainly antibodies and inhibitors. ability of an organism to elicit an adaptive immune response. post-translational modification of proteins comprising the covalent addition of lactate to an amino acid residue (hitherto described for lysine) of a protein. Histone lactylation has been reported to epigenetically modulate gene expression. subset of genes expressed by macrophages that differentiate and acquire the so-called 'M2' immunosuppressive/wound-healing phenotype. tumors bearing inactivating mutations in genes encoding proteins involved in DNA mismatch repair. stimulated by mutations in one or more proto-oncogenes or tumor suppressor gene-encoded proteins. subset of exhausted CD8+T cells characterized by TCF-1+ and PD-1+ expression. These cells have stem cell-like properties (e.g., self-renewal capacity) and increased effector function compared with terminally exhausted CD8+ T cells. oxygen-containing molecules that are, or can give rise to, free radicals. ROS can damage and alter function of nucleotides, proteins, and membrane lipids. resemble those of stem cells, such a self-renewal capacity and the ability to differentiate into other cells. tumors exhibiting very poor infiltration of CD8+ T cells, especially in cancer cell-rich areas. T cell fate characterized by a progressive decrease of effector functions, elevated and sustained expression of immune inhibitory receptors, impaired memory and self-renewal capacity, transcriptional and epigenetic reprogramming, and altered metabolic profile. inheritable alteration in the DNA of a cell that involves the substitution of a nucleotide containing a purine for a pyrimidine or vice versa. heterogenous population of cancer cells (parenchyma), non-malignant cells (stromal cells), extracellular matrix, and signaling molecules in specific areas of tumors. number of cancer cell-specific nonsynonymous somatic mutations in a tumor, per megabase of a genetic region of interest. Such mutations drive the formation of neoantigens (i.e., antigens derived from novel mutated peptides or proteins and, therefore, are not present in the normal genome). metabolic phenotype caused by altered expression of enzymes and transporters associated with the urea cycle; limits the function of the urea cycle, promoting diversion of nitrogen toward pyrimidine synthesis, increasing mutagenesis, cell proliferation, and ICB responses.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
李健的应助被科研通管家采纳,获得10
2秒前
华仔的应助被wu采纳,获得10
2秒前
天天快乐的应助被FZ采纳,获得10
2秒前
CipherSage的应助被科研通管家采纳,获得10
2秒前
打打的应助被科研通管家采纳,获得300
2秒前
李健的应助被科研通管家采纳,获得10
2秒前
2秒前
情怀的应助被孤独听雨的猫采纳,获得10
2秒前
fan的应助被科研通管家采纳,获得10
2秒前
上官若男的应助被小陈呀采纳,获得10
2秒前
科研通AI6.3的应助被科研通管家采纳,获得100
3秒前
今后的应助被科研通管家采纳,获得10
3秒前
烟花的应助被科研通管家采纳,获得10
3秒前
JamesPei的应助被科研通管家采纳,获得10
3秒前
DW的应助被科研通管家采纳,获得10
3秒前
小蘑菇的应助被科研通管家采纳,获得10
3秒前
徐枘发布了新的文献求助10
3秒前
无极微光的应助被科研通管家采纳,获得20
3秒前
3秒前
xioabu发布了新的文献求助10
3秒前
Owen的应助被科研通管家采纳,获得10
3秒前
烟花的应助被科研通管家采纳,获得10
4秒前
orixero的应助被坦率的凉面采纳,获得10
4秒前
wanci的应助被科研通管家采纳,获得10
4秒前
4秒前
星辰大海的应助被科研通管家采纳,获得10
4秒前
Jasper的应助被科研通管家采纳,获得10
4秒前
4秒前
丘比特的应助被科研通管家采纳,获得10
4秒前
在水一方的应助被科研通管家采纳,获得10
4秒前
Ava的应助被科研通管家采纳,获得10
4秒前
田様的应助被科研通管家采纳,获得10
5秒前
夏目完成签到,获得积分10
5秒前
深情安青的应助被科研通管家采纳,获得10
5秒前
Owen的应助被科研通管家采纳,获得10
5秒前
5秒前
lli完成签到,获得积分10
5秒前
羅马完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183730
求助须知:如何正确求助?哪些是违规求助? 9572975
关于积分的说明 21828453
捐赠科研通 7780887
什么是DOI,文献DOI怎么找? 3434086
关于科研通互助平台的介绍 2558276
邀请新用户注册赠送积分活动 2480557